Kamal Sahu, MD
Hematology & Oncology · Salt Lake City, UTNPI 1922584440
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,159 of the $1,359 with a category attached, or 85.3%. 16 manufacturers reported payments, led by AstraZeneca at 26.8% of the total. Reporting peaked in 2021 at $502 and has fallen 74.8% since, to $126 in 2025. That places this record below the midpoint for hematology & oncology clinicians in UT, where the typical reported total is $2,350.
Across 46 payments — averaging $29.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$364
- Johnson & Johnson$302
- Seagen Inc.$200
- Janssen Scientific Affairs, LLC$108
- AbbVie$102
- Gilead$44
- plus $239 from 10 others
What the payments were for
- Food & beverage$1,15985%
- Education$20015%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 18 | $364 |
| Johnson & Johnson | 6 | $302 |
| Seagen Inc. | 2 | $200 |
| Janssen Scientific Affairs, LLC | 1 | $108 |
| AbbVie | 4 | $102 |
| Gilead | 2 | $44 |
| Biogen | 2 | $41 |
| Shire North American Group Inc | 2 | $39 |
| Boehringer Ingelheim | 2 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Bristol Myers Squibb | 1 | $18 |
| Pfizer | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Novartis | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$131
How this compares
$1,359 in reported general payments places this provider in the 40th percentile of 77 hematology & oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisone | 11 | $19 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Salt Lake City
- Douglas SborovSalt Lake City$473K
- Daniel CourielSalt Lake City$229K
- Shiven PatelSalt Lake City$223K
- Neeraj AgarwalSalt Lake City$159K
- Benjamin MaughanSalt Lake City$142K
- Schickwann TsaiSalt Lake City$137K
- Heloisa SoaresSalt Lake City$111K
- Daanish HodaSalt Lake City$80K
- Tsewang TashiSalt Lake City$69K
- Finn PetersenSalt Lake City$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.